JP2005532392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532392A5 JP2005532392A5 JP2004519682A JP2004519682A JP2005532392A5 JP 2005532392 A5 JP2005532392 A5 JP 2005532392A5 JP 2004519682 A JP2004519682 A JP 2004519682A JP 2004519682 A JP2004519682 A JP 2004519682A JP 2005532392 A5 JP2005532392 A5 JP 2005532392A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000002830 appetite depressant Substances 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- -1 rosaglitazone Chemical compound 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39332702P | 2002-07-02 | 2002-07-02 | |
| PCT/US2003/020489 WO2004005262A2 (en) | 2002-07-02 | 2003-06-30 | New neuropeptide y y5 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532392A JP2005532392A (ja) | 2005-10-27 |
| JP2005532392A5 true JP2005532392A5 (enExample) | 2006-07-20 |
| JP4498133B2 JP4498133B2 (ja) | 2010-07-07 |
Family
ID=30115567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519682A Expired - Fee Related JP4498133B2 (ja) | 2002-07-02 | 2003-06-30 | 新規神経ペプチドｙｙ５レセプターアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7157472B2 (enExample) |
| EP (1) | EP1601666A2 (enExample) |
| JP (1) | JP4498133B2 (enExample) |
| CN (1) | CN1678608A (enExample) |
| AU (1) | AU2003251739A1 (enExample) |
| CA (1) | CA2490470A1 (enExample) |
| MX (1) | MXPA05000200A (enExample) |
| WO (1) | WO2004005262A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257541B1 (en) * | 2008-02-22 | 2013-08-14 | F. Hoffmann-La Roche AG | Modulators for amyloid beta |
| CA2736924C (en) | 2008-10-09 | 2016-06-28 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| JP5378532B2 (ja) * | 2008-11-10 | 2013-12-25 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環γ−セクレターゼモジュレーター |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| UA114711C2 (uk) | 2011-05-13 | 2017-07-25 | Еррей Біофарма Інк. | Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| EP2922844B1 (en) | 2012-11-13 | 2018-01-10 | Array Biopharma, Inc. | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| HRP20161613T1 (hr) | 2012-11-13 | 2017-01-13 | Array Biopharma, Inc. | Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| EP3076789A4 (en) * | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| WO2015089800A1 (en) | 2013-12-19 | 2015-06-25 | Eli Lilly And Company | Fluorophenyl pyrazol compounds |
| RU2719489C2 (ru) | 2014-05-15 | 2020-04-17 | Эррэй Биофарма Инк. | 1-((3S,4R)-4-(3-ФТОРФЕНИЛ)-1-(2-МЕТОКСИЭТИЛ)ПИРРОЛИДИН-3-ИЛ)-3-(4-МЕТИЛ-3-(2-МЕТИЛПИРИМИДИН-5-ИЛ)-1-ФЕНИЛ-1Н-ПИРАЗОЛ-5-ИЛ)МОЧЕВИНА В КАЧЕСТВЕ ИНГИБИТОРА TrkA КИНАЗЫ |
| KR101689382B1 (ko) | 2015-05-11 | 2016-12-23 | 코오롱인더스트리 주식회사 | 이동통신단말 착신 알림 기능을 구비한 스마트 백 및 이를 활용한 착신 알림 방법 |
| WO2017114377A1 (zh) * | 2015-12-29 | 2017-07-06 | 四川海思科制药有限公司 | 一种苯基杂环衍生物及其在医药上的用途 |
| WO2020243060A1 (en) * | 2019-05-30 | 2020-12-03 | The Regents Of The University Of California | Methods of treating hyperlipidemia conditions with netrin-1 compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| NZ201395A (en) | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
| US4616014A (en) | 1981-10-22 | 1986-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| DE3601196A1 (de) | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
| CA2046628A1 (en) | 1989-02-08 | 1990-08-09 | Dee W. Brooks | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| DE4023215A1 (de) | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
| JPH0841006A (ja) | 1994-08-05 | 1996-02-13 | Nisshin Flour Milling Co Ltd | ジウレア誘導体 |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| DE69735710T2 (de) | 1996-02-13 | 2007-03-29 | Abbott Laboratories, Abbott Park | Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten |
| US5792138A (en) | 1996-02-22 | 1998-08-11 | Apollo Camera, Llc | Cordless bipolar electrocautery unit with automatic power control |
| AU5135998A (en) * | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
| US6166038A (en) * | 1996-12-13 | 2000-12-26 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
| EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION |
| US6329395B1 (en) * | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| ES2255330T3 (es) | 1998-11-10 | 2006-06-16 | MERCK & CO., INC. | Espiroindolinas como antagonistas del receptor y5. |
| ATE306481T1 (de) * | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| JP3411262B2 (ja) * | 1999-08-20 | 2003-05-26 | 萬有製薬株式会社 | 新規スピロ化合物 |
| US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
| AU2002234056B2 (en) * | 2000-12-21 | 2005-04-07 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
-
2003
- 2003-06-30 WO PCT/US2003/020489 patent/WO2004005262A2/en not_active Ceased
- 2003-06-30 CN CNA038206277A patent/CN1678608A/zh active Pending
- 2003-06-30 MX MXPA05000200A patent/MXPA05000200A/es active IP Right Grant
- 2003-06-30 EP EP03763043A patent/EP1601666A2/en not_active Withdrawn
- 2003-06-30 CA CA002490470A patent/CA2490470A1/en not_active Abandoned
- 2003-06-30 AU AU2003251739A patent/AU2003251739A1/en not_active Abandoned
- 2003-06-30 JP JP2004519682A patent/JP4498133B2/ja not_active Expired - Fee Related
- 2003-06-30 US US10/609,638 patent/US7157472B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532392A5 (enExample) | ||
| JP2005510563A5 (enExample) | ||
| CA2467857A1 (en) | Piperidine-based mch antagonists for treatment of obesity and cns disorders | |
| CA2454830A1 (en) | Substituted urea neuropeptide y y5 receptor antagonists | |
| JP2005511656A5 (enExample) | ||
| JP2005507918A5 (enExample) | ||
| JP5845318B2 (ja) | 嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物 | |
| JP2012505896A5 (enExample) | ||
| JP2005509024A5 (enExample) | ||
| JP2005538123A5 (enExample) | ||
| JP2005535641A5 (enExample) | ||
| CA2443672A1 (en) | Aryl and biaryl piperidines used as mch antagonists | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| WO2009006315A1 (en) | Modulators of atp-binding cassette transporters for treating cystic fibrosis | |
| JP2004516314A5 (enExample) | ||
| CA2432809A1 (en) | Heteroaryl urea neuropeptide y y5 receptor antagonists | |
| JP2007501269A5 (enExample) | ||
| JP2007518720A5 (enExample) | ||
| PE20080069A1 (es) | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) | |
| HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
| ME01294B (me) | Nova jedinjenja i kompozicije i metode upotrebe | |
| JP2012530765A5 (enExample) | ||
| JP2010505783A5 (enExample) | ||
| JP2007537301A5 (enExample) | ||
| EP2049567A2 (en) | Human glp-1 mimetibodies, compositions, methods and uses |